Istituto Giannina Gaslini
Genova, 16147, Italy
Location status: Recruiting
Location contact
Riccardo Haupt, MD
CONTACT
Stefania Sorrentino
CONTACT
NCT Number: NCT02559804
To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes
Interested in participating?
Request InfoUp to 18 year
All sexes
Observational
Genova, 16147, Italy
Location status: Recruiting
Riccardo Haupt, MD
CONTACT
Stefania Sorrentino
CONTACT
Multi-centre, observational, prospective study registry. About 15% of patients with peripheral neuroblastic tumour present with extradural SCI, of whom approximately 60% are symptomatic. Since SCI may progress to irreversible paraplegia, early diagnosis and prompt treatment is of critical importance.1-3 The treatment options include chemotherapy, neurosurgical decompression and radiation therapy. All may relieve epidural compression, but there is no consensus on which to use first in the individual patient. However, the choice of the treatment could be relevant in the perspective of reducing to the minimum the risk of long-term sequelae.4 Guidelines for the diagnostic work-up and treatment of SCI for International Society of Paediatric Oncology European Neuroblastoma (SIOPEN) neuroblastoma patients were already available in the "guidelines for the treatment of patients with localized resectable neuroblastoma and analysis of prognostic factors" (LNESG1 Protocol), back in 1994,5 although it is unknown how they were applied in the SIOPEN Centres. These guidelines have been reformulated in occasion of the recently activated "European Low and Intermediate risk Neuroblastoma" (LINES Protocol).
There are few publications addressing the diagnosis and treatment of SCI; most are retrospective studies, case reports, or reviews that may be affected by reporting bias.1-9 Therefore new guidelines could be designed based on the information derived from a prospective data collection of newly diagnosed patients.
For this study Spinal Canal Involvement (SCI) is defined when, referring to an axial plane of the spinal cord MRI scan (Figure 1), the tumour extends into the vertebral canal and goes beyond a mentally drown ellipsoid (red circle) passing through the cortical bone of both anterior and posterior arches of the vertebra. This involvement is called "intraspinal" or, better, "intracanal".
Patient data to be collected and included in the corresponding Forms
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
survival and late effects
Time frame: for 5 years
American Spinal Injury Association ASIA impairment scale
Time frame: for 5 years
using Common Terminology Criteria for Adverse Events v. 4.0
Time frame: for 5 years
using Face, Legs, Activity, Cry, Consolability scale (FLACC scale)
Time frame: 5 years
event free survival
Time frame: 5 years
overall survival
Contact information is provided by the study sponsor or research team.
Associazione Italiana Ematologia Oncologia Pediatrica
Other
Acronym: NB-SCI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07549425
Neuroblastic Tumors
Hefei, Anhui, China
View Trial DetailsNCT06798532
Ganglioneuroblastoma, Ganglioneuroma
Amiens, France
View Trial Details